Proactive Research analyst Ed Stacey talks to Katie Pilbeam about his research on Mydecine Innovations Group which is a biotech and life sciences company.
The firm develop and commercialise new therapies for mental health and other conditions.
In recent months the company has achieved further progress in maturing its intellectual property (IP) portfolio and adding new proprietary compounds.